Clinical trials: Choroid Diseases
Age Related Macular Degeneration
Usage of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00596388)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Macular Degeneration
Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece
This is a prospective, observational, multi-center, study. The study will be conducted in approximately 12 ophthalmological clinics and practices throughout Greece.
- Trial name
- PERSEUS-GR (NCT02821247)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Greece
- Volunteers
- 119 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
Age-Related Macular Degeneration
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
- Trial name
- NCT00725686
- Testing
- PF-04523655
- Where
- 11 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Quark Pharmaceuticals
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with…
- Trial name
- PCV (NCT00674323)
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis
Age-related Macular Degeneration, Choroidal Neovascularization
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to…
- Trial name
- NCT00712491
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen Inc.
Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD)
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular…
- Trial name
- NCT00504959
- Testing
- ranibizumab
- Where
- 36 sites in Australia, Belgium and 8 more
- Volunteers
- 234 people
- Sponsor
- Novartis
Age Related Macular Degeneration (AMD), Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established…
- Conditions
- Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)
- Trial name
- PERSPECTIVES (NCT00327470)
- Testing
- Pegaptanib Sodium 0.3 mg
- Where
- 58 sites in Austria, Belgium and 13 more
- Volunteers
- 288 people
- Sponsor
- Pfizer